Magnetically Controlled Transport of Nanoparticles in Solid Tumor Tissues and Porous Media Using a Tumor-on-a-Chip Format.

This study addresses issues in developing spatially controlled magnetic fields for particle guidance, synthesizing biocompatible and chemically stable MNPs and enhancing their specificity to pathological cells through chemical modifications, developing personalized adjustments, and highlighting the potential of tumor-on-a-chip systems, which can simulate tissue environments and assess drug efficacy and dosage in a controlled setting. The research focused on two MNP types, uncoated magnetite nanoparticles (mMNPs) and carboxymethyl dextran coated superparamagnetic nanoparticles (CD-SPIONs), and evaluated their transport properties in microfluidic systems and porous media. The original uncoated mMNPs of bimodal size distribution and the narrow size distribution of the fractions (23 nm and 106 nm by radii) were demonstrated to agglomerate in magnetically driven microfluidic flow, forming a stable stationary web consisting of magnetic fibers within 30 min.

Hybrid-integrated devices for mimicking malignant brain tumors ("tumor-on-a-chip") for development of targeted drug delivery and personalized therapy approaches.

Acute and requiring attention problem of oncotheranostics is a necessity for the urgent development of operative and precise diagnostics methods, followed by efficient therapy, to significantly reduce disability and mortality of citizens. A perspective way to achieve efficient personalized treatment is to use methods for operative evaluation of the individual drug load, properties of specific tumors and the effectiveness of selected therapy, and other actual features of pathology. Among the vast diversity of tumor types-brain tumors are the most invasive and malignant in humans with poor survival after diagnosis.

Prognosis of patients with Hodgkin lymphoma and indeterminate response to PD-1 inhibitor therapy: considerations for application of LYRIC criteria in real clinical practice.

PD-1 inhibitors have shown unconventional response patterns in classic Hodgkin lymphoma (cHL). These include the phenomenon of pseudoprogression, highlighting the need for specialized response criteria such as the LyRIC, which stringened definitions for disease progression with introduction of indeterminate response category. Despite their potential utility, these provisional criteria are currently underutilized and require further refinement through clinical practice data collection.

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.

Patients And Methods: Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy.